<?xml version="1.0" encoding="utf-8"?>
<html madcap:lastblockdepth="4" madcap:lastheight="878" madcap:lastwidth="701" xmlns:madcap="http://www.madcapsoftware.com/Schemas/MadCap.xsd">
 <head>
 </head>
 <body>
  <h1>
   Indivior PLC
  </h1>
  <div style="display: none;">
   <table cellspacing="1" class="TableStyle-dnb_tablestyle_1" style="mc-table-style: url('../Resources/TableStyles/dnb_tablestyle_1.css');">
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <thead>
     <tr class="TableStyle-dnb_tablestyle_1-Head-Header1">
      <th class="TableStyle-dnb_tablestyle_1-HeadE-Column1-Header1">
       DUNS
      </th>
      <th class="TableStyle-dnb_tablestyle_1-HeadE-Column1-Header1">
       Hoovers ID
      </th>
      <th class="TableStyle-dnb_tablestyle_1-HeadD-Column1-Header1">
       Tier
      </th>
     </tr>
    </thead>
    <tbody>
     <tr class="TableStyle-dnb_tablestyle_1-Body-Body1">
      <td class="TableStyle-dnb_tablestyle_1-BodyB-Column1-Body1" style="text-align: center;">
        220392796
      </td>
      <td class="TableStyle-dnb_tablestyle_1-BodyB-Column1-Body1" style="text-align: center;">
       163363
      </td>
      <td class="TableStyle-dnb_tablestyle_1-BodyA-Column1-Body1" style="text-align: center;">
       2
      </td>
     </tr>
    </tbody>
   </table></div><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Synopsis.flsnp" /><p>
   Helping individuals conquer addiction is Indivior's calling. A global specialty pharmaceutical company, Indivior improves patient lives by pioneering innovative and accessible therapies for addiction and related mental health disorders. Indivior is the global leader in the treatment of opioid dependence. To date, Indivior has provided an estimated 5 million patients effective treatment options with the SUBOXONE Film (world's first approved pharmaceutical prescription sublingual film product); SUBOXONE Tablet (an orphan drug for maintenance treatment of opioid dependence) and SUBUTEX Tablet (Indivior's first product for the treatment of opioid dependence) medications.
  </p><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Change in Company Type.flsnp" />
  <p>
   Reckitt Benckiser Pharmaceuticals spun off from the
   <company id="42008">
    Reckitt Benckiser Group
   </company>
   in 2014. As Indivior, it was then listed on the
   <company id="100694">
    London Stock Exchange
   </company>
   .
  </p>
  <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Geographic Reach.flsnp" />
  <p>
   Indivior has a presence in more than 30 countries in North America; Europe, Middle East and Africa; Australasia; and Asia.
  </p>
  <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Strategy.flsnp" />
  <p>
   The company spends about 6% of its annual revenues on research and development. Indivior has a growing pipeline to address the chronic diseases of addiction, as well as therapies for alcohol dependence, cocaine intoxication, schizophreniam and opioid overdose. In 2014 it had six product candidates in development and 14 clinical trials underway.
  </p>
  <p>
   Company Background
  </p>
  <p>
   The company traces its roots to the Buprenorphine Business Group, which was established by the  Reckitt Benckiser Group in 1994 to develop buprenorphine for the treatment of opioid dependence.
  </p>
 <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /></body>
</html>
